No Cover Image

Journal article 177 views 89 downloads

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial

Daisuke Yabe, Katsumi Iizuka, Michael Baxter, Daisuke Watanabe, Hideaki Kaneto

Journal of Diabetes Investigation, Volume: 12, Issue: 11, Pages: 1992 - 2001

Swansea University Author: Michael Baxter

  • 58676.pdf

    PDF | Version of Record

    © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License

    Download (354.96KB)

Check full text

DOI (Published version): 10.1111/jdi.13563

Abstract

IntroductionTreatments for type 2 diabetes targeting baseline glucose levels but not postprandial glucose can result in normalized fasting blood glucose but suboptimal overall glycemic control (high glycated hemoglobin): residual hyperglycemia. In Japanese patients with type 2 diabetes the predomina...

Full description

Published in: Journal of Diabetes Investigation
ISSN: 2040-1116 2040-1124
Published: Wiley 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58676
first_indexed 2021-11-15T15:14:20Z
last_indexed 2021-12-08T04:18:53Z
id cronfa58676
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-12-07T15:41:50.0776386</datestamp><bib-version>v2</bib-version><id>58676</id><entry>2021-11-15</entry><title>iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post&#x2010;hoc analysis of the LixiLan JP&#x2010;L trial</title><swanseaauthors><author><sid>2e6934882a9e8e415a50bf31f8c91545</sid><firstname>Michael</firstname><surname>Baxter</surname><name>Michael Baxter</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-11-15</date><abstract>IntroductionTreatments for type 2 diabetes targeting baseline glucose levels but not postprandial glucose can result in normalized fasting blood glucose but suboptimal overall glycemic control (high glycated hemoglobin): residual hyperglycemia. In Japanese patients with type 2 diabetes the predominant pathophysiology is a lower insulin secretory capacity, and residual hyperglycemia is common with basal insulin treatment. Single-injection, fixed-ratio combinations of glucagon-like peptide-1 receptor agonists and basal insulin have been developed. iGlarLixi (insulin glargine 100 units/mL [iGlar]: lixisenatide ratio of 1 unit:1&#x2009;&#xB5;g) is for specific use in Japan. Post-hoc analysis of the LixiLan JP-L trial (NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation with residual hyperglycemia.Materials and MethodsOutcomes at week 26 (based on the last observation carried forward) were assessed in patients in the modified intent-to-treat population with baseline residual hyperglycemia.ResultsOverall, 83 (32.5%) patients in the iGlarLixi group and 79 (30.7%) patients in the iGlar group had baseline residual hyperglycemia. The proportion of patients with residual hyperglycemia at week 26 decreased to 15.7% in the iGlarLixi group, and increased to 36.9% in the iGlar group. Patients in the iGlarLixi group had significantly greater reductions in glycated hemoglobin compared with the iGlar group (&#x2212;0.72% difference between groups; P&#x2009;&lt;&#x2009;0.0001).ConclusionsNew data from this post-hoc analysis of the JP-L trial show that treatment with the fixed-ratio combination iGlarLixi reduced the proportion of Japanese patients with residual hyperglycemia from baseline to week 26 and significantly reduced glycated hemoglobin vs similar doses of iGlar alone.</abstract><type>Journal Article</type><journal>Journal of Diabetes Investigation</journal><volume>12</volume><journalNumber>11</journalNumber><paginationStart>1992</paginationStart><paginationEnd>2001</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2040-1116</issnPrint><issnElectronic>2040-1124</issnElectronic><keywords>Hyperglycemia; Japan; Type 2 diabetes</keywords><publishedDay>3</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-11-03</publishedDate><doi>10.1111/jdi.13563</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm/><funders>Sanofi Identifier: FundRef 10.13039/100004339</funders><lastEdited>2021-12-07T15:41:50.0776386</lastEdited><Created>2021-11-15T15:10:06.5890170</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Daisuke</firstname><surname>Yabe</surname><order>1</order></author><author><firstname>Katsumi</firstname><surname>Iizuka</surname><order>2</order></author><author><firstname>Michael</firstname><surname>Baxter</surname><order>3</order></author><author><firstname>Daisuke</firstname><surname>Watanabe</surname><order>4</order></author><author><firstname>Hideaki</firstname><surname>Kaneto</surname><order>5</order></author></authors><documents><document><filename>58676__21542__bc06d1e4c2cc4448a111d4a0609ab72e.pdf</filename><originalFilename>58676.pdf</originalFilename><uploaded>2021-11-15T15:11:45.1732939</uploaded><type>Output</type><contentLength>363476</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-12-07T15:41:50.0776386 v2 58676 2021-11-15 iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial 2e6934882a9e8e415a50bf31f8c91545 Michael Baxter Michael Baxter true false 2021-11-15 IntroductionTreatments for type 2 diabetes targeting baseline glucose levels but not postprandial glucose can result in normalized fasting blood glucose but suboptimal overall glycemic control (high glycated hemoglobin): residual hyperglycemia. In Japanese patients with type 2 diabetes the predominant pathophysiology is a lower insulin secretory capacity, and residual hyperglycemia is common with basal insulin treatment. Single-injection, fixed-ratio combinations of glucagon-like peptide-1 receptor agonists and basal insulin have been developed. iGlarLixi (insulin glargine 100 units/mL [iGlar]: lixisenatide ratio of 1 unit:1 µg) is for specific use in Japan. Post-hoc analysis of the LixiLan JP-L trial (NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation with residual hyperglycemia.Materials and MethodsOutcomes at week 26 (based on the last observation carried forward) were assessed in patients in the modified intent-to-treat population with baseline residual hyperglycemia.ResultsOverall, 83 (32.5%) patients in the iGlarLixi group and 79 (30.7%) patients in the iGlar group had baseline residual hyperglycemia. The proportion of patients with residual hyperglycemia at week 26 decreased to 15.7% in the iGlarLixi group, and increased to 36.9% in the iGlar group. Patients in the iGlarLixi group had significantly greater reductions in glycated hemoglobin compared with the iGlar group (−0.72% difference between groups; P < 0.0001).ConclusionsNew data from this post-hoc analysis of the JP-L trial show that treatment with the fixed-ratio combination iGlarLixi reduced the proportion of Japanese patients with residual hyperglycemia from baseline to week 26 and significantly reduced glycated hemoglobin vs similar doses of iGlar alone. Journal Article Journal of Diabetes Investigation 12 11 1992 2001 Wiley 2040-1116 2040-1124 Hyperglycemia; Japan; Type 2 diabetes 3 11 2021 2021-11-03 10.1111/jdi.13563 COLLEGE NANME COLLEGE CODE Swansea University Sanofi Identifier: FundRef 10.13039/100004339 2021-12-07T15:41:50.0776386 2021-11-15T15:10:06.5890170 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Daisuke Yabe 1 Katsumi Iizuka 2 Michael Baxter 3 Daisuke Watanabe 4 Hideaki Kaneto 5 58676__21542__bc06d1e4c2cc4448a111d4a0609ab72e.pdf 58676.pdf 2021-11-15T15:11:45.1732939 Output 363476 application/pdf Version of Record true © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License true eng https://creativecommons.org/licenses/by-nc/4.0/
title iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
spellingShingle iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
Michael Baxter
title_short iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
title_full iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
title_fullStr iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
title_full_unstemmed iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
title_sort iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
author_id_str_mv 2e6934882a9e8e415a50bf31f8c91545
author_id_fullname_str_mv 2e6934882a9e8e415a50bf31f8c91545_***_Michael Baxter
author Michael Baxter
author2 Daisuke Yabe
Katsumi Iizuka
Michael Baxter
Daisuke Watanabe
Hideaki Kaneto
format Journal article
container_title Journal of Diabetes Investigation
container_volume 12
container_issue 11
container_start_page 1992
publishDate 2021
institution Swansea University
issn 2040-1116
2040-1124
doi_str_mv 10.1111/jdi.13563
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description IntroductionTreatments for type 2 diabetes targeting baseline glucose levels but not postprandial glucose can result in normalized fasting blood glucose but suboptimal overall glycemic control (high glycated hemoglobin): residual hyperglycemia. In Japanese patients with type 2 diabetes the predominant pathophysiology is a lower insulin secretory capacity, and residual hyperglycemia is common with basal insulin treatment. Single-injection, fixed-ratio combinations of glucagon-like peptide-1 receptor agonists and basal insulin have been developed. iGlarLixi (insulin glargine 100 units/mL [iGlar]: lixisenatide ratio of 1 unit:1 µg) is for specific use in Japan. Post-hoc analysis of the LixiLan JP-L trial (NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation with residual hyperglycemia.Materials and MethodsOutcomes at week 26 (based on the last observation carried forward) were assessed in patients in the modified intent-to-treat population with baseline residual hyperglycemia.ResultsOverall, 83 (32.5%) patients in the iGlarLixi group and 79 (30.7%) patients in the iGlar group had baseline residual hyperglycemia. The proportion of patients with residual hyperglycemia at week 26 decreased to 15.7% in the iGlarLixi group, and increased to 36.9% in the iGlar group. Patients in the iGlarLixi group had significantly greater reductions in glycated hemoglobin compared with the iGlar group (−0.72% difference between groups; P < 0.0001).ConclusionsNew data from this post-hoc analysis of the JP-L trial show that treatment with the fixed-ratio combination iGlarLixi reduced the proportion of Japanese patients with residual hyperglycemia from baseline to week 26 and significantly reduced glycated hemoglobin vs similar doses of iGlar alone.
published_date 2021-11-03T02:34:49Z
_version_ 1821461749855944704
score 11.064692

Similar Items